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Anadenanthera Colubrina vell Brenan: 
anti-Candida and antibiofilm activities, 
toxicity and therapeutical action
Abstract: We evaluated the antifungal and antibiofilm potential of 
the hydroalcoholic extract of bark from Anadenanthera colubrina (vell.) 
Brenan, known as Angico, against Candida spp. Antifungal activity was 
evaluated using the microdilution technique through the Minimum 
Inhibitory and Fungicide Concentrations (MIC and MFC). The 
antibiofilm potential was tested in mature biofilms formed by Candida 
species and analyzed through the counting of CFU/mL and scanning 
electron micrograph (SEM). In vivo toxicity and therapeutic action 
was evaluated in the Galleria mellonella model. The treatment with the 
extract, in low doses, was able to reduce the growth of planktonic cells 
of Candida species. MIC values range between 19.5 and 39 µg/mL and 
MFC values range between 79 and 625 µg/mL. In addition was able 
to reduce the number of CFU/mL in biofilms and to cause structural 
alteration and cellular destruction, observed via SEM. A. colubrina 
showed low toxicity in the in vivo assay, having not affected the 
viability of the larvae at doses below 100mg/kg and high potential in 
the treatment of C. albicans infection. Considering its high antifungal 
potential, its low toxicity and potential to treatment of infections in in 
vivo model, A. colubrina extract is a strong candidate for development of 
a new agent for the treatment of oral candidiasis.
Keywords: Infection Control; Biofilms; Candida; Phytotherapy.
Introduction
Candidiasis is a fungal infection caused by Candida species and 
Candida albicans (C. albicans) is the variety most associated with it. Changes 
of normal conditions in the oral environment can favor the growth of 
Candida with a change of its commensal state into pathogenic. Most of 
the time, these changes are related to immunological imbalances in the 
host.1,2,3 Candidiasis may be local (mucocutaneous) or systemic, and 
present in acute, chronic and in association with other types of lesions.4 
C. albicans is part of the oral microbiota and is isolated in approximately 
80% of healthy individuals.2,3 Candidiasis is one of the most frequent 
opportunistic infections in immunocompromised patients, especially 
Acquired Immunodeficiency Syndrome (AIDS) and cancer patients,5 with a 
prevalence of 9 to 31% and 20%, respectively. In addition, it occurs in about 
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5% to 7% of children in the first years of life and is 
quite frequent in users of the total dental prosthesis.6,7
In relation to the treatment of oral candidiasis, 
it is possible to mention drugs such as azole derivatives 
(fluconazole, miconazole and itraconazole) and polyene 
(nystatin), which despite having good therapeutic 
action, may exhibit undesirable, mainly dose-related 
toxicity.8,9 The dose-dependent toxicity reported 
to antifungals is only one of the most reported 
limitations to these drugs. Long-term therapy may 
lead to more serious risks, including recurrent drug 
interactions, organic dysfunction, skin reactions 
and malignancies.10,11 Thus, an ideal antifungal 
agent should have no toxicity or reduced toxicity to 
human cells.12 From this perspective, medicinal plants 
represent a vast source of active compounds, with 
potential for the development of new and effective 
pharmaceutical forms.
Anadenanthera colubrina (vell) Brenan (A. colubrina), 
popularly known as Angico, represents a plant 
widely used in folk medicine for the treatment 
of inflammation, respiratory problems related to 
infection (cough, influenza, and bronchitis), diarrhea 
and toothache.13,14 It is considered as a plant of 
therapeutic potential, but still little explored from 
the pharmacological point of view.15 In the world, 
the species occurs to the South of the line of the 
Equator, and in Brazil, from the Northeastern to 
the Southeastern regions. It is a woody species 
typical of the Caatinga biome.16 Caatinga is a biome 
that exists only in Brazil, composed of xenophilic 
vegetation adapted to the scarcity of water. Despite 
its exclusivity, it is currently the Brazilian biome with 
the smallest total area protected by conservation 
units compared to other biomes.17 Caatinga has 
many species at risk of extinction and the scientific 
contribution evidencing its natural riches will 
assist in the preservation processes of this rich 
biome that is being invaded by cattle breeding and 
unsustainable extractivism.
Recent studies have shown that A. colubrina 
has promising therapeutic properties, such as 
antifungal,18,19,20 anti-inflammatory and antinociceptive 
activities21, the last two having been confirmed in an 
animal model. In a previous study, our group verified 
that A. colubrina has a strong antifungal potential 
against C. albicans, inhibiting biofilm formation 
with changes in its morphology.19 These results 
have signaled this plant as a possible source of 
active compounds for the development of antifungal 
formulations for the treatment of oral candidiasis. 
In this study, we evaluate antifungal and antibiofilm 
action in different species of the genus Candida, 
as well as the toxicity level of the A. colubrina extract, 
in order for it to be considered as an alternative for 
treatment of oral candidiasis.
Methodology
Preparation of Hydroalcoholic extract
Anadenanthera colubrina (vell) Brenan was collected 
in September in the Queimadas city, geographically 
located in the Borborema Plateau, Paraíba State, 
Northeastern region of Brazi l (7º 22’ 25”S, 
35º 59’ 32” W), which is part of the caatinga biome. 
A voucher specimen was deposited in the Manuel 
de Arruda Câmara Herbarium of the Paraíba State 
University under n° 667/ACAM. The bark was 
dehydrated, moistened and immersed in 80% ethanol 
(100 g/250 mL) for 48h at room temperature. Then it 
was filtered and the residues were immersed in 80% 
ethyl alcohol. The three final extraction phases were 
concentrated in a rotary evaporator, freeze-dried 
and stored at -20ºC.
Microorganisms and susceptibilidy assay
Microorganisms used: Candida albicans MYA 2876, 
Candida albicans ATCC 90028, Candida parapsilosis 
ATCC 22019 e Candida krusei ATCC 6258. Two 
clinical isolates of Candida albicans, named 1 
and 2, removed from oral candidiasis lesions 
of patients from the school clinic of the State 
University of Paraíba were also included, under 
the approval of the institution’s ethics committee, 
under number: 51779315.7.0000.5187 (Dec 15th, 
2015). The antimicrobial activity was identified via 
microdilution in broth, determining the Minimum 
Inhibitory Concentration (MIC) (CLSI, M27-A2)22 
and the Minimum Fungicidal Concentration (MFC). 
The test was performed on 96 well microplates 
containing using RPMI 1640 medium (Angus 
Buffers and Biochemicals, Niagara Falls, USA). 
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The extract was diluted in 20% DMSO and later 
in RMPI. The final DMSO concentration at wel 
was <1% which would not affect the viability of 
the yeasts. Serial dilutions were made, obtaining 
concentrations of 5000 and 4.882 μg/mL. Nystatin 
(Sigma-Aldrich) was used as positive control. An 
inoculum of 5x103 cells/mL was considered, which 
is the well that fell to 2.5x103 cells/mL, standardized 
in spectrophotometer. The plates were incubated at 
37°C for 24 h. MIC was defined via visual method 
initially considering the change in color of the 
culture medium from pink to yellow. Then, 30 µL 
of resazurin 0.1% (Sigma-Aldrich, St. Louis, USA) 
was added to the wells. For determination of MFC, 
an aliquot (20 μL) of each well with concentrations 
equal to and greater than the MIC were seeded on 
a dextrose agar medium incubated at 37°C for 24 h.
Antibiofilm activity assay 
Candida biofilm formation was induced in 
96-well microplates. A inoculum (between 107 
and 108 cells/mL) in a Yeast Nitrogen Base (YNB) 
culture medium (Sigma-Aldrich) supplemented 
with glucose, were distributed in each well and 
incubated at 37 °C for 24 h.23 After this time, the 
supernatant was discarded and the biofilm washed 3 
times with a 0.9% NaCl solution. The treatment was 
performed with A. colubrina extract at MIC-based 
concentrations (100 and 500 x MIC). The extract 
was diluted in 20% dimethylsulfoxide (DMSO) 
and then in a RPMI 1640 culture medium. After 
a dilution the concentration of DMSO dropped to 
less than 1% in the wells. Nystatin at concentration 
of 100 x MIC for each strain was used as positive 
control. The biofilm was treated for 24 h at 37°C. It 
was then removed, diluted in a 0.9% NaCl solution 
and seeded in a Petri dish containing Saboraud 
dextrose agar medium and incubated at 37 °C for 
24 h for counting CFU/mL. 
In vivo toxicity and treatment of 
systemic infection in Galleria mellonella 
(G. mellonella) 
An in vivo model of G. mellonella was used to 
evaluate the acute toxicity of A. colubrina extract 
in a manner similar to that previously described, 
with some modifications.24,25 Different doses of the 
extract were tested in increasing order to obtain LD 
50. A random selection of 10 healthy-looking larvae 
weighing between 0.2 and 0.3 g was made for each 
group. A volume of 5 µL of the extract or control 
(20% v/v, DMSO) was injected into the left proleg 
of the hemocele using a 25 μL Hamilton Syringe 
(Hamilton, Reno, NV). We evaluate the therapeutic 
potential of A. colubrina extract to treatment of 
systemic C. albicans infection. A culture of C. albicans 
ATCC 90028 was grown overnight in BHI broth. The 
inoculum was diluted in 0.9% NaCl and standardized 
to 5x107 cells in a spectrophotometer. Four groups 
of 10 larvae received 10 µl of inoculum injected in 
the last left proleg of each larva and then in the 
last right proleg the following treatments, after one 
hour: group 1 (A. colubrina 50x MIC - 975 µg/mL), 
grupo 2 (A. colubrina 100x MIC – 1,950 µg/mL) group 
3 (A. (Amphotericin 100x MIC – 50 µg/mL) and Group 
4 (0.9% NaCl solution).The larvae were incubated 
at 30°C and their survival was evaluated every 9 h 
until the maximum time of 48 h. The larvae with a 
high degree of melanization and lack of movement 
when touched were counted as dead.
Analysis of cell morphology
The biofilms were formed (Lab-Tek, Nunc, 
Naperville, USA), using the method described in 
item Antibiofilm activity assay. Thus we evaluated 
the following samples: biofilm of C. albicans 90028 
treated with A. colubrina 100xMIC, treated with A. 
colubrina 500xMIC and negative control without 
treatment. They were treated with the extract 
at concentrations 100 x MIC and 500 x MIC for 
24 h. The cells were fixed in 3% glutaraldehyde at 
room temperature for 12 h. The biofilm was then 
dehydrated in increasing concentrations of ethanol, 
metallized with gold and examined through 
Scanning Electron Microscopy (SEM) (SEM JEOL 
JSM 5600LV, JEOL Tokyo, Japan).
Statistical analysis
The assays were performed in triplicate and in three 
independent experiments. The statistical analyses 
for evaluation of biofilm reduction were applied at 
the follow conditions: the type of variable for UFC 
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quantification is quantitative continuous numerical; 
data are parametrical with normal distribution by 
means of Lilliefors test (BioEstat software) for all 
groups non-significant (ns) with p < 0.05 (α value). 
Subsequently, an analysis of variance and post-hoc 
analysis were used in accordance with the Tukey 
test, with a significance level of 5 % (α < 0.05). For 
the G. mellonella model, Kaplan–Meier killing curves 
were plotted on GraphPad Prism 5.0 and estimations 
of differences in survival were compared using the 
log-rank test.
Results
A. colubrina extract inhibited the growth of all 
Candida species tested at 19.5 – 5000 μg/mL range 
concentrations (Table), and C. albicans exhibited the 
lowest values of MIC (19.5 µg/mL). However, the 
extract was fungicidal and in low concentrations only 
for the species C. parapsilosis and C. krusei, while for 
the other species the result was negligible.
A. colubrina extract showed activity against biofilm 
formed by species of Candida. The best results were 
observed in the species C. parapsilosis and C. krusei 
(biofilm treated with the extract at a concentration 
of 500xMIC = 19,500 μg/mL). Only for these species 
and concentrations the extract could totally kill 
all microorganisms. However, all biofilms species 
underwent alteration and decrease in the number 
of CFU/mL when treated with A. colubrina extract 
(Figure 1).
The microorganisms that exhibited a reduction 
in the quantity of viable cells, after treatment with 
A. colubrina, were submitted to microscopic analysis 
via SEM. As seen in Figure 2, the results were 
similar for the recorded effect typically found in C. 
albicans ATCC 90028 (Figure 2). The SEM showed 
the appearance of biofilm structural alterations 
such as cell destruction, holes and channels and 
decrease of the hyphatic form in relation to the 
control (Figure 2A to 2F).
About the toxicity of the A. colubrina extract, in 
the G. mellonella in vivo model, low acute systemic 
toxicity was observed. In the antimicrobial 
therapeutic doses, the extract did not affect the 
survival of the larvae until the 72 h period (p > 0.05). 
Only at high doses up to 5 g/kg (LD50), the larvae 
died in the range from 50%–100% (LD100 = 10 g/kg) 
(p < 0.0001). The vehicle used to solubilize the 
extract (DMSO 1%), as well as doses of the extract 
below 100 mg/kg, did not affect the viability of 
the larvae (p > 0.05) (Figure 3a). Nystatin showed 
toxicity at concentrations above 1 g/kg. The nystatin 
concentration required to kill 50% of the larvae 
(LD50) was 2.5 g/kg (Figure 3b).
A. colubrina extract at 100xMIC concentration 
was able to treat and protect 20% of the larvae. This 
value was similar to that of the systemic antifungal 
amphotericin, at 100xMIC concentration. A. colubrina 
50x MIC prevented the death of 10% of the group. 
The group treated with the dilution vehicle had 100% 
death of the sample and the group without infection 
Table. Distribution of minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) of A. colubrina 




µg|mL Ratio µg|mL Ratio
Candida albicans MYA 2876 19.5|625 32 1|2 2
Candida albicans ATCC 90028 19.5|625 32 1|2 2
Candida albicans (clinical strain 1) 19.5|625 32 3|6 2
Candida albicans (clinical strain 2) 39|625 16 3|6 2
Candida parapsilosis ATCC 22019 39|79 2 1|2 2
Candida krusei ATCC 6258 39|39 1 1|2 2
Fungicide (MFC/MIC< 4) or fungistatic (MFC/MIC > 4).23
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and that received only the vehicle presented 100% 
viability (Figure 4).
Discussion
A. columbirna, a plant known as Angico and used 
by the people of the Brazilian caatinga region for the 
treatment of respiratory problems and inflammation, 
was previously flagged as a plant with strong 
growth-inhibitory capacity for the C. albicans specie.19,20 
We show here that this ability to inhibit growth also 
extends to other species of Candida non-albicans, such 
as C. parapsilosis and C. krusei (Table).
We found MIC values for C. albicans, which 
differ from those previously found19,20 and our 
current results are more relevant. This difference 
may be related to the use of different strains 
between studies. Another factor that may have 
influenced this difference is the dilution vehicle 
of the extract. Previous studies used 40% alcohol 
and in this study, we used 1% DMSO. It is possible 
that DMSO may have solubilized the components 
of the extract better, potentializing its action. Here, 
we showed very low MIC values of A. colubrina 
(Table) against C. albicans strains (19 μg/mL for 
stock strains and one clinical strain and 39 μg/mL 
for another clinical strain). In addition, equally 
low values were found for non-albicans species, 
considered as emerging (39 μg/mL for C. parapsilosis 
and C. krusei). It has been considered that MIC 
values below 100 μg/mL are deemed as very 
promising for a phytocomposite.26
Figure 1. Antibiofilm activity of the A. colubrina extract evidencing a discrete reduction of cell viability (- Log) in C. albicans MYA 
2876 (a), C. albicans ATCC 90028 (b) and C. albicans clinical strains 1 (c) and 2 (d), and reduction of cell viability in 100% for 
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C. albicans is the species associated with infections 
and also the most studied, and its clinical strains are 
more resistant than the corresponding collection.27 For 
comparison purposes, we also evaluated the effect 
of A. colubrina on two clinical strains of C. albicans; 
in this case, one strain had the same result as that of 
Figure 2. SEM of C. albicans ATCC 90028 showing the cellular morphology. In the first column: untreated biofilm (a), treated with 
A. colubrina 100x MIC = 1950 ug/mL (c) and biofilm treated with A. colubrina 500x MIC = 9750 ug/mL (e), in a 500x view. In 
the second column, the same findings may be observed at a 5,000x view . 
15kV ×500 50µm 90028   C–
15kV ×500 50µm 90028 100×
15kV ×5,000 5µm 90028 100×
15kV ×5,000 5µm 90028   C
15kV ×500 50µm 90028 500×
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the collection while the other was a dilution above. 
This data shows that the A. colubrina extract is equally 
effective for inhibiting the growth of wild strains 
of Candida despite its greater virulence, evidencing 
the effectiveness of the compound and suggesting 
a potential for clinical efficacy.
The ability of the Candida species to develop 
as a biofilm reflects clinical consequences because 
microorganisms show resistance to antifungal therapy 
at usual therapeutic doses. Thus, biofilm formation is 
considered one of the main virulence factors associated 
with C. albicans, which contributes to increased 
Figure 3. In vivo systemic toxicity of the A.colubrina, increasing doses from 50 mg/kg to 10 g/kg (A); and increasing nystatin doses 
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Figure 4. Treatment of systemic infection by C. albicans with amphotericin 100xMIC (50 µg/mL), A. colubrina 50xMIC (975 µg/













Inf+A. colubrina (1950 µg/mL)
Inf+Amphotericin (50 µg/mL)








7Braz. Oral Res. 2019;33:e023
Anadenanthera Colubrina vell Brenan: anticandida and antibiofilm activities, toxicity and therapeutical action
mortality in patients immunocompromised with 
candidiasis.28,29 A. colubrina at concentrations higher 
than MIC can affect the biofilm of all Candida species. 
C. albicans, considered the most present specie in 
the oral cavity of humans,30 was the most sensitive 
in the planktonic form and the least sensitive in the 
biofilm form. Indeed, C. albicans is reported to form 
quantitatively larger and qualitatively more complex 
biofilms than other Candida species.31 However, there 
was a significant reduction in the number of CFU / mL 
in C. albicans biofilm treated with A. colubrina.
Although C. albicans is described as the main Candida 
specie related to candidiasis, non-albicans species 
demonstrate virulence factors previously attributed 
to C. albicans, reflecting its increase in antifungal 
resistance.32 In addition, species of Candida non-albicans 
are increasingly reported in cases of fungemia.33 Thus, 
the discovery of new antifungals with effects also on 
species of Candida non-albicans is necessary. The A. 
colubrina extract showed a promising ability to alter 
the biofilm of Candida non-albicans. The extract was 
able to cause severe decrease in cellular viability for 
the C. krusei specie at a 100x MIC concentration and 
100% decrease at a 500x MIC concentration. The same 
occurred with C. parapsilosis. In view of that, C. krusei 
have an intrinsic resistance to fluconazole34 and C. 
parapsilosis showed high MIC values for echinocandins, 
a recent antifungal class,35 whereas A. colubrina shows 
itself to be a potent alternative source of active principles 
capable of preventing the growth of these species in 
low concentrations, as well as destroying their biofilms 
in higher concentrations. Concentrations 100 and 
500 x the MIC may appear high, but, it is still below 
the concentration that was toxic in the in vivo model 
of G. mellonella.
Our findings have shown an antibiofilm activity 
superior to that shown by other studies with natural 
products.36,37 Although we used higher concentrations, 
we proved that they are well below the dose considered 
toxic in our model in vivo.
In vitro studies have the limitation of not accurately 
reflecting the conditions of the oral environment, 
such as the presence of saliva, the host’s immune 
component, and multispecies biofilms with different 
species of Candida and bacteria. However, the extract 
of A. colubrina was able to alter the integrity of 
the biofilms, significantly reducing the number of 
CFU/mL in all the concentrations tested for the 
biofilms of the Candida species analyzed in this study. 
This data shows that the extract has a remarkable 
antibiofilm activity in vitro, in biofilm formed by 
species of the genus Candida. There is evidence 
that most of the conditions resulting from fungal 
infections are associated with their ability to form 
biofilm.38 Previously, we evaluate the phytochemical 
composition of the A. colubrina extract.  The results 
showed a high total polyphenol content (53.18% gallic 
acid equivalents). Tannin content was 8.77% catechin 
equivalents and flavonoid content was 0.28% quercetin 
equivalents.19 The biological activities evaluated here 
appear to be related to these compounds.
The SEM showed that the biofilm formed by C. 
albicans is affected after treatment with A. colubrina. 
Visually, there is little difference in relation to the 
two concentrations tested (100 and 500x MIC). This 
data is similar to that found in the CFU/mL count of 
this same strain, where the difference between the 
two concentrations is discrete. However, in relation 
to the control, a significant alteration of the biofilm 
is observed when treated with A. colubrina extract. 
It is possible to observe the appearance of structural 
alterations such as the presence of holes and channels 
in the biofilm, which may have been provoked by the 
cellular destruction in the regions where the extract 
was able to penetrate. In addition, hyphae decreased, 
indicating a possible decrease in virulence since the 
formation of hyphae is related to tissue invasion.
Data from the in vivo G. mellonella toxicity model 
suggest that A. colubrina shows a promising safety 
index. Only high doses of the A. colubrina extract 
(5, 7 and 10 g/kg) affected the viability of the larvae, 
higher than those tested in the antibiofilm assay. 
G. mellonella has become a widely used method for 
the primary evaluation of substance toxicity, drug 
efficacy and virulence of microorganisms.39 
To avaliate the therapeutic potential of A. colubrina 
extract we conduced a in vivo assay to treatment 
of Candida infection in G. mellonella. the extract of 
A. colubrina was able to treat infection in larvae 
showing a  similar  result to amphotericin. As shown 
by the survival curve, A. colubrina not only prevented 
the death of 20% of the sample but provided the 
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most life time for the larvae that died in relation 
to amphotericin. For example, at 24 h and 48 h the 
group treated with A. colubrina had 50% and 30% of 
live larvae, respectively, while the group treated with 
amphotericin at the time 24 h had only 20% of live 
larvae. At the end of the experiment, both treatments 
kept 20% of the live larvae. Thus, considering that 
A. colubrina is a crude extract and amphotericin a 
monodrug, we can consider that A. colubrina has 
a high therapeutic potential in the treatment of C. 
albicans infection. Studies with larger animals need 
to be performed to confirm this initial data. However, 
our data serve as a basis for reducing the number 
of animals needed in future tests, since G. mellonella 
is an effective alternative model for this purpose.39
Thus, considering a possible topical use of the 
extract and its low toxicity in this model in vivo, these 
data support the idea that the extract of A. colubrina 
may have a high safety potential. It is noticeable 
that the crude extract of this plant has promising 
therapeutic potential. However, it is still little explored 
pharmacologically. Issues such as the mechanism 
of action, posology and therapeutic indications still 
need to be better studied.15
Based on the in vivo toxicity test results, the 
concentrations tested in the biofilm assays were 
extrapolated to 100 and 500x MIC. This is the first 
study showing the potential for systemic toxicity 
in vivo of the extract of Anadenanthera colubrina vell. 
Brenan and its antifungal activity and antibiofilm on 
different Candida species. It is important to remember 
that treatment with a monodrug, such as antifungal 
agents, is exposure to a specific molecule that may be 
in high concentrations (causing high dose-dependent 
toxicity). Although natural products also have 
dose-dependent toxicity, there is a big difference. 
In natural products the active principles are in low 
concentrations within the crude extract and may 
even be acting synergistically, as suggested by the 
work of Lima et al.,19 who did not verify improvement 
of the action after fractionation of the A. colubrina 
extract. Small amounts of different molecules acting 
synergistically suggest a product with lower potential 
for toxicity and other adverse effects.
Ethnopharmacology mentions the therapeutic 
potential of A. colubrina and its use by the population 
for the treatment of conditions that affect health, 
such as inflammation, bronchitis, influenza, 
cough, diarrhea, and toothache.13,14 Considering the 
anti-Candida potential and toxicity results, showed 
in our study, there may be a large margin of safety 
for the therapeutic use of this extract, especially in 
relation to oral candidiasis, since most cases of oral 
candidiasis are resolved with topical application of 
antifungal agents.9
Thus, considering the high anti-Candida potential 
and low toxicity potential of the A. colubrina extract, 
our findings stimulate further studies to confirm 
the hypothesis that the extract has efficacy in the 
treatment of candidiasis and large safety margin. The 
elucidation of the safety and therapeutic potential of 
this plant will add scientific value, ensuring its use 
in an effective and safe way for the treatment of oral 
candidiasis. Clinical studies with larger animals and 
humans are needed to define information such as 
posology and mode of use.
Conclusion
The results show that the extract of the shell of 
A. colubrina has antifungal and antibiofilm properties 
against different Candida species, low systemic 
toxicity in vivo and high potential in the treatment of 
C. albicans infection. This data which shows a potential 
safety for its possible use. In view of the increased 
resistance of the Candida species to antifungal agents 
currently used for the treatment of candidiasis, and 
the increasing appearance of fungemia caused by 
albicans and non-albicans species, A. colubrina, can be 
considered as a promising source of active principles 
for the treatment of candidiasis. Their compounds 
can be used in the development of a phytotherapic 
treatment or of allopathic drugs. Clinical studies are 
necessary to confirm its efficacy and safety in the 
treatment of oral candidiasis.
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